Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Caribou Biosciences, Inc. CRBU NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
58/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.00
+230.2%

Caribou Biosciences, Inc. (CRBU) is a Biotechnology company in the Healthcare sector, currently trading at $2.12. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is CRBU = $7 (+230.2% upside).

Valuation: CRBU trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25).

Financials: revenue is $11M, +29.9%/yr average growth. Net income is $148M (loss), growing at -16%/yr. Net profit margin is -1327.4% (negative). Gross margin is 67.3% (-6.4 pp trend).

Balance sheet: total debt is $27M against $122M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 5.71 (strong liquidity). Debt-to-assets is 15.5%. Total assets: $175M.

Analyst outlook: 9 / 9 analysts rate CRBU as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 35/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

$7.00
▲ 230.19% Upside
Average Price Target
The 12-month price target for Caribou Biosciences, Inc. is $7.00.

CRBU SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 35/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CRBU

✓
VALUE Pass
100/100
CRBU trades at a trailing Price-to-Earnings (P/E) of -1.3 (S&P 500 average ~25). Forward PEG -0.2 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $7, implying +230.2% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
CRBU: +29.9%/yr revenue is, -16%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet CRBU: Debt-to-Equity (D/E) ratio 0.22 (conservative), Current ratio is 5.71 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
35/100
CRBU: Gross margin is 67.3% (-6.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 9 / 9 analysts rate CRBU as buy (100%). Analyst consensus target is $7 (+230.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CRBU: Net profit margin is -1327.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.66-3.535
Volume2.4M
Avg Volume (30D)1.23M
Market Cap$204.87M
Beta (1Y)2.46
Share Statistics
EPS (TTM)-1.59
Shares Outstanding$93.39M
IPO Date2021-07-23
Employees147
CEORachel E. Haurwitz
Financial Highlights & Ratios
Revenue (TTM)$11.16M
Gross Profit$7.51M
EBITDA$-132.55M
Net Income$-148.13M
Operating Income$-136.19M
Total Cash$139.34M
Total Debt$27.23M
Net Debt$14.87M
Total Assets$175.37M
Price / Earnings (P/E)-1.3
Price / Sales (P/S)18.36
Analyst Forecast
1Y Price Target$7.00
Target High$7.00
Target Low$7.00
Upside+230.2%
Rating ConsensusBuy
Analysts Covering9
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS1420381089

Price Chart

Track all markets on TradingView
CRBU
Caribou Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.66 52WK RANGE 3.54

People Also View

CRSP
CRSP
CRISPR Therapeutics AG
$56.86
+3.70%
 BEAM
BEAM
Beam Therapeutics Inc.
$30.30
+0.40%
 ADPT
ADPT
Adaptive Biotechnologies Corporation
$14.53
+2.83%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.78
+3.65%
 VERV
VERV
Verve Therapeutics, Inc.
$11.13
+0.27%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 PRME
PRME
Prime Medicine, Inc.
$3.70
+1.09%
 EDIT
EDIT
Editas Medicine, Inc.
$3.39
+5.94%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message